$2,580,000 of AMGEN INC lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 Issues related to corporate and international tax Public Law 115-97, Tax Cuts and Jobs Act Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025 Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025"
You can find more data on corporate lobbying on Quiver Quantitative.
AMGN Congressional Stock Trading
Members of Congress have traded $AMGN stock 6 times in the past 6 months. Of those trades, 2 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAVID TAYLOR has traded it 5 times. They made 1 purchase worth up to $15,000 on 01/16 and 4 sales worth up to $60,000 on 02/26, 01/29, 12/03.
- REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 10/24.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
AMGN Insider Trading Activity
AMGN insiders have traded $AMGN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by insiders over the last 6 months:
- ESTEBAN SANTOS (EVP, Operations) has made 0 purchases and 2 sales selling 54,792 shares for an estimated $20,772,595.
- MURDO GORDON (EVP, Global Commercial Ops) sold 6,879 shares for an estimated $2,317,071
- NANCY A. GRYGIEL (SVP & CCO) has made 0 purchases and 2 sales selling 3,139 shares for an estimated $1,058,666.
- MATTHEW C. BUSCH (VP, Finance & CAO) sold 1,000 shares for an estimated $375,790
- RACHNA KHOSLA (SVP, Business Development) sold 890 shares for an estimated $299,255
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AMGN Hedge Fund Activity
We have seen 1,388 institutional investors add shares of AMGN stock to their portfolio, and 1,256 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 13,593,173 shares (-74.7%) from their portfolio in Q4 2025, for an estimated $4,449,181,454
- CAPITAL WORLD INVESTORS added 4,302,237 shares (+22.9%) to their portfolio in Q4 2025, for an estimated $1,408,165,192
- JPMORGAN CHASE & CO removed 1,936,240 shares (-45.8%) from their portfolio in Q4 2025, for an estimated $633,750,714
- ROCKEFELLER CAPITAL MANAGEMENT L.P. added 1,785,595 shares (+354.6%) to their portfolio in Q4 2025, for an estimated $584,443,099
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC removed 1,739,567 shares (-12.8%) from their portfolio in Q4 2025, for an estimated $569,377,674
- PACER ADVISORS, INC. removed 1,613,121 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $527,990,634
- BLACKROCK, INC. added 1,361,706 shares (+3.0%) to their portfolio in Q4 2025, for an estimated $445,699,990
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AMGN Analyst Ratings
Wall Street analysts have issued reports on $AMGN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BMO Capital issued a "Outperform" rating on 12/03/2025
- Piper Sandler issued a "Overweight" rating on 11/14/2025
To track analyst ratings and price targets for AMGN, check out Quiver Quantitative's $AMGN forecast page.
AMGN Price Targets
Multiple analysts have issued price targets for $AMGN recently. We have seen 14 analysts offer price targets for $AMGN in the last 6 months, with a median target of $350.5.
Here are some recent targets:
- Michael Yee from UBS set a target price of $400.0 on 04/13/2026
- Terence Flynn from Morgan Stanley set a target price of $326.0 on 04/10/2026
- Vamil Divan from Guggenheim set a target price of $351.0 on 04/09/2026
- Carter Gould from Cantor Fitzgerald set a target price of $350.0 on 04/08/2026
- Akash Tewari from Jefferies set a target price of $350.0 on 03/10/2026
- Emily Field from Barclays set a target price of $350.0 on 02/20/2026
- Mohit Bansal from Wells Fargo set a target price of $375.0 on 02/19/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
